BioUtah News
-
bioMérieux announces nomination of two new Executive Committee members to lead Medical Affairs and R&D
bioMérieux announces nomination of two new Executive Committee members to lead Medical Affairs and R&D
-
Constant Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of TXA127 in Ischemic Stroke Recovery
Constant Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of TXA127 in Ischemic Stroke Recovery
-
ATL Technology: MD&M West 2024: Tech Talk and Meeting Registration
ATL Technology: MD&M West 2024: Tech Talk and Meeting Registration
-
ARUP’s Julio Delgado, MD, MS, Selected as Inaugural Harry R. Hill, MD, Presidential Endowed Chair-Holder
ARUP’s Julio Delgado, MD, MS, Selected as Inaugural Harry R. Hill, MD, Presidential Endowed Chair-Holder
-
Thermo Fisher Scientific Receives GMP approval from the Italian Medicines Agency (AIFA) for its Manufacturing facility of RNA-Based Products in Monza, Italy
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients.
-
BD Helps Advance Health Equity for Women in Kenya through Critical Cancer Screening
Collaboration with Kenya Ministry of Health National Cancer Institute Aims to Expand Access to Diagnostics, Reduce Cervical Cancer…
-
NUSANO NAMES ROHAN JAIN AS COMMERCIAL GENERAL MANAGER
Nusano Names Rohan Jain as Commercial General Manager.
-
Thermo Fisher Scientific Unveils Industry’s First Off-the-Shelf Validated Software Solution to Automate Cell Therapy Manufacturing Workflows
Gibco CTS Cellmation Software digitally connects instruments from across Thermo Fisher’s cell therapy portfolio to streamline and automate…
-
Update on kidneyIntelX.dkd Local Coverage Determination Consideration
Local Coverage Determination would result in contracted coverage for an estimated additional five million Medicare patients with Type…
-
First Patient Enrolled in Merit Medical’s MOTION Study
First Patient Enrolled in Merit Medical’s MOTION Study
-
bioMérieux acquires LUMED to reinforce its software portfolio in the fight against antimicrobial resistance
bioMérieux acquires LUMED to reinforce its software portfolio in the fight against antimicrobial resistance
-
ENPICOM and Carterra Advance Antibody Screening by Integrating Biophysical Characterization and Repertoire Sequencing Analysis
By allowing Carterra’s superior epitope, binding affinity, and kinetic information to occupy the same view as sequence information,…
-
National Registry Names Intermountain Health’s Transplant Program as Nation’s Top Program for Successfully Matching Donated Kidneys to Patients
National Registry Names Intermountain Health’s Transplant Program as Nation’s Top Program for Successfully Matching Donated Kidneys to Patients
-
Merit Medical Announces Process for Chief Executive Officer Succession Planning
Merit Medical Announces Process for Chief Executive Officer Succession Planning
-
Spectrum Solutions Names Bill Phillips as New Chief Executive Officer
Spectrum Solutions Names Bill Phillips as New Chief Executive Officer
-
MasterControl Solutions Inc., Expands in Salt Lake County
$40 million capex, 155 jobs, Project Orange
-
Halia Therapeutics Dosed its First Patient in Phase 2a Clinical Trial of HT-6184, a First-in-Class NLRP3-Inhibitor, for the Treatment of Lower-Risk Myelodysplastic Syndromes
LEHI, Utah /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed…
-
BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
BD MiniDraw™ Capillary Blood Collection System Enables Lab-Quality Blood Testing from Less Invasive Method than Venous Collection in…
-
Halia Therapeutics co-founder David J. Bearss Featured in Utah Business
Utah Business recently featured Halia Therapeutics co-founder David Bearss in their Founder Series
-
RxCell Announces $4.6M Investment from DMR Global Venture and Regenosis, Plans for Second Raise of $15M for IND Testing in Q4 2023
SINGAPORE–(BUSINESS WIRE)–RxCell, a pioneering biotech company focusing on cellular therapeutics for age-related diseases, today proudly announces a $4,600,000…
-
Culmination Bio Raises $10M From Amgen Ventures and Merck Global Health Innovation Fund to Bring Longitudinal Health Data to Biopharma
Culmination Bio has over 40 years of biospecimen data and counting, paired with clinical data from patient EHRs,…
-
SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK – ENROLLMENT TO STOP DUE TO SUCCESS
SALT LAKE CITY, Dec. 6, 2023 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on…
-
BD to Present Next Installment of BD Innovates Series: Spotlight on Pharmaceutical Systems
BD to Present Next Installment of BD Innovates Series: Spotlight on Pharmaceutical Systems
-
Next-Generation Microcatheter for Embolic Agent Delivery Cleared by the FDA
Next-Generation Microcatheter for Embolic Agent Delivery Cleared by the FDA
-
BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency
SiteRite™ 9 Ultrasound System Delivers Enhanced Image Quality and Vessel Assessment Tools to Aid in First Attempt IV…
-
Seek Labs Announces Completion of Office Expansion to Support Business Growth
Seek Labs Announces Completion of Office Expansion to Support Business Growth
-
Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity
Metabolexis focuses on GLP-1 weight loss and type 2 diabetic drug discoveries to improve accessibility and meet unprecedented…
-
Biolexis Secures $10 Million in Series A Funding to Advance Metabolic Drug Development
LED BY CLARKE CAPITAL, THE NEW FUNDING ROUND WILL ACCELERATE THE COMPANY’S DRUG DISCOVERY PIPELINE
-
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
-
Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit
Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit
-
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk®…
-
Innovative Research, Inclusive Trials, and New Funding Drives Hope for People with Parkinson’s Disease
PhotoPharmics Secures $16 Million Investment Led by Kickstart to Fund Pivotal Clinical Trial for FDA Market Authorization
-
2023 Utah Life Sciences Summit Recap and Gallery
BioUtah yesterday held its 2023 Utah Life Sciences Summit, presented by Mayer Brown. Every year, the Summit is…
-
Xenter Unveils Groundbreaking Investigational Dual Sensor Wireless GuideWire for Minimally Invasive TAVR Procedures at TCT 2023
Revolutionizing Data Collection in Cardiology with Proprietary Wireless Ecosystem
-
2023 BioUtah Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
SALT LAKE CITY – November 3, 2023 – BioUtah today announced the winners of its 2023 Life Sciences…
-
ATL Announces New VP of Human Resources
Springville, Utah, October 27, 2023—ATL Technology, a dynamic and rapidly expanding company specializing in medical device development and…
-
BD Introduces Advanced Ultrasound Technology to Help Drive First-Stick Success for IV Insertions
BD Prevue™ II System Equips Clinicians with Connected Ultrasound Technology to Drive More Intuitive IV Placement and Control…
-
Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
First-in-Human Study of Novel Oral Dual-Acting Antibody in Development for Treatment of Patients with Inflammatory Bowel Disease SALT…
-
BioUtah Announces New Board Leadership and Five New Board Members
SALT LAKE CITY – October 27, 2023 –BioUtah, Utah’s trade association serving the state’s life sciences community, announced…
-
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
Partnership covers development of lab-developed and distributable kit-based companion diagnostic tests Combined strengths in assay development, clinical testing,…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8M Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial…
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
